

Neuro-oncology at the Crossroads

Wai-Hoe Ng,¹FRACS (Neurosurg), Siew-Ju See,^{2,3}MRCP (UK)

The notion of a tumour in the brain is a most terrifying prospect for most individuals and many physicians. Yet brain tumour is the second most common form of malignancy in childhood, and accounts for the 3rd or 4th most frequent cause of cancer death among middle-aged adults. More optimal control of primary malignancies has also contributed to a phenomenal increase in the incidence of metastatic brain tumours. The advent of AIDS has also contributed to the rise in lymphoma of the central nervous system (CNS).

The field of neuro-oncology could not have progressed without concomitant advances in the field of neuro-imaging, neuroanaesthesia, surgical techniques, radiation therapeutics and neuro-oncology.

There have been great strides in neuroradiological techniques in functional and metabolic imaging of brain tumours. The functional imaging techniques of positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance spectroscopy (MRS) are able to quantify various aspects of brain tumour metabolism. Information regarding tumour blood flow, tumour growth rate, degree of oxygenation, pH, and chemical composition, such as lactate (Lac), choline (Cho), N-acetylaspartate (NAA), phosphocreatine (PCr), creatine (Cr) and lipids (Lip) can be now obtained.¹

Awake anaesthetic and surgical techniques now allow safer and more radical surgery for tumours located in the eloquent cortex, that were previously either managed expectantly or only offered a biopsy for histological diagnosis.^{2,3}

Adjuvant therapies after surgical resection often include radiation therapy and chemotherapy. Better radiation therapy techniques now permit the delivery of effective doses of radiation with reduced neurotoxicity.⁴ The chemotherapeutic armamentarium now includes more drugs capable of crossing the blood brain barrier to reach effective concentrations. The role of chemotherapy as part of upfront treatment for newly diagnosed glioblastoma (astrocytoma), the commonest and most aggressive malignant primary brain tumour in adults, has been established in randomised

controlled trials. For other types of gliomas, patients and doctors will benefit from the new data and clarification on the role of chemotherapy for newly diagnosed tumours obtained from recently completed clinical trials. When gliomas recur, carefully selected additional interventions can help preserve physical and cognitive functions. This issue includes timely updates of these developments.^{5,6}

It is clear that there is better overall patient satisfaction and possibly better patient outcomes when patients are treated in a multidisciplinary setting. Few other disciplines demonstrate this philosophy more convincingly than the neuro-oncology model. Back et al⁷ have certainly demonstrated in this issue that a holistic multi-disciplinary approach can produce superior patient care at all levels.

There is no controversy that the most radical advances in the field of neuro-oncology are now taking place in the molecular realm. Carcinogenesis is a complex interplay of aberrant signalling pathways resulting from of ligand-receptor interactions that induce tumour proliferation and cellular migration, promote angiogenesis, inhibit apoptosis, and confer cellular survival and chemoresistance. The concept of a cancer stem cell with an intrinsic capacity for unlimited self-renewal and the ability to initiate and drive tumour progression is now challenging the traditional concept of cancer homogeneity.⁸ These advances in molecular biology leave no doubt that the future battles of neuro-oncology will not be fought at the bedside or operating room but in the laboratory.

REFERENCES

1. Nagar VA, Ye JR, Xu MS, Ng WH, Yeo TT, Ong PL, et al. Multivoxel MR spectroscopic imaging – distinguishing intracranial tumours from non-neoplastic disease. *Ann Acad Med Singapore* 2007;36:309-13.
2. Low D, Ng I, Ng WH. Awake craniotomy under local anaesthesia and monitored conscious sedation for resection of brain tumours in eloquent cortex- outcomes in 20 patients. *Ann Acad Med Singapore* 2007;36: 326-31.
3. See JJ, Lew TWK, Kwek TK, Chin KJ, Wong MFM, Liew QY, et al. Anaesthetic management of awake craniotomy for tumour resection.

¹ Department of Neurosurgery, National Neuroscience Institute, Singapore

² Department of Neurology, National Neuroscience Institute (Singapore General Hospital campus), Singapore

³ National Cancer Centre, Singapore

Address for Correspondence: Dr Ng Wai Hoe, Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433.

Email: Wai_Hoe_Ng@nni.com.sg

- Ann Acad Med Singapore 2007;36:319-25.
4. Back MF, Baggerley S, Park E, Wei R. Optimising radiation therapy techniques for tumours of the central nervous system. *Ann Acad Med Singapore* 2007;36:332-7.
 5. See SJ, Gilbert MR. Chemotherapy in adults with gliomas. *Ann Acad Med Singapore* 2007;36:364-9.
 6. See SJ, Ty A, Wong MC. Salvage chemotherapy in progressive high-grade astrocytoma. *Ann Acad Med Singapore* 2007;36:343-6.
 7. Back MF, Ang ELL, Ng WH, See SJ, Lim CCT, Tay LL, et al. Improvements in quality of care resulting from a formal multidisciplinary tumour clinic in the management of high-grade glioma. *Ann Acad Med Singapore* 2007;36:347-51.
 8. Tang C, Chua CLM, Ang BT. Insights into the cancer stem cell model of glioma tumorigenesis. *Ann Acad Med Singapore* 2007;36:352-7.
-